• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    40 Stocks Moving In Friday's Mid-Day Session

    6/3/22 12:07:35 PM ET
    $ACOR
    $AMLX
    $BQ
    $BTOG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACOR alert in real time by email

     

    Gainers

    • Turning Point Therapeutics, Inc. (NASDAQ:TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
    • Energy Focus, Inc. (NASDAQ:EFOI) shares jumped 32.8% to $1.4740 after declining around 9% on Thursday.
    • Nutex Health, Inc. (NASDAQ:NUTX) gained 20.6% to $11.11.
    • Sprague Resources LP (NYSE:SRLP) shares jumped 19.8% to $18.96 after the company announced an agreement to be acquired by Hartree Partners for $19 per common unit.
    • Kubient, Inc. (NASDAQ:KBNT) gained 19.5% to $1.19.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) gained 18.9% to $11.62 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035.
    • Boqii Holding Limited (NYSE:BQ) jumped 15.5% to $2.26.
    • Harpoon Therapeutics, Inc. (NASDAQ:HARP) jumped 14.7% to $2.27.
    • Mirati Therapeutics, Inc. (NASDAQ:MRTX) gained 14% to $45.82.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose 14.6% to $10.42. Nurix Therapeutics will present trial in progress posters for three clinical programs Jun. 4 and 5.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) gained 13.6% to $7.50. Iovance Biotherapeutics Director Wayne P Rothbaum acquired a total of 1,000,000 shares at at an average price of $6.60.
    • Society Pass Incorporated (NASDAQ:SOPA) jumped 13.1% to $2.3626 after the company announced it acquired Gorilla Networks.
    • Houston American Energy Corp. (NYSE:HUSA) jumped 12% to $4.9600.
    • Calavo Growers, Inc. (NASDAQ:CVGW) gained 11.7% to $37.08 following better-than-expected Q2 results.
    • Evofem Biosciences, Inc. (NASDAQ:EVFM) surged 11.6% to $0.3839.
    • Okta, Inc. (NASDAQ:OKTA) rose 11.3% to $104.28 after the company reported better-than-expected Q1 sales results. The company also issued Q2 sales guidance above analyst estimates.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 10.6% to $1.36 after dropping 13% on Thursday.
    • Quanex Building Products Corporation (NYSE:NX) gained 8.7% to $22.55 after the company reported better-than-expected Q2 results and issued FY22 sales guidance above estimates.
    • The Marygold Companies, Inc. (NYSE:MGLD) rose 8.5% to $1.5950. Marygold Companies, last month, posted Q1 earnings of $0.02 per share.
    • StoneCo Ltd. (NASDAQ:STNE) rose 6.6% to $11.11 after the company reported first-quarter revenue growth of 138.6% year-over-year to R$2.07 billion, above the mid-range of the company’s guidance of R$1.85 billion and R$1.9 billion.
    • CN Energy Group. Inc. (NASDAQ:CNEY) rose 6.1% to $1.6011 after dipping 26% on Thursday.

     

    Losers

    • Bit Origin Limited (NASDAQ:BTOG) shares dipped 41.9% to $0.5001 after the company priced a 9,803,922 share offering at $0.51 per share.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares fell 35.2% to $0.39 after the company reported pricing of $4 million underwritten public offering.
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) fell 19.8% to $0.6750.
    • HashiCorp, Inc. (NASDAQ:HCP) shares dipped 18.8% to $33.51 after the company reported Q1 earnings results and issued guidance.
    • JOANN Inc. (NASDAQ:JOAN) dropped 18.1% to $6.47 after the company said Q1 EPS results were lower year over year and reported worse-than-expected Q1 sales results.
    • Novavax, Inc. (NASDAQ:NVAX) fell 17.2% to $46.36. The U.S. FDA published briefing documents on Novavax Covid-19 vaccine for individuals aged 18 and older.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) dropped 15.6% to $0.8436. Zosano Pharma recently announced it filed a voluntary petition for relief under chapter 11.
    • Rallybio Corporation (NASDAQ:RLYB) declined 15.1% to $11.23. Rallybio announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) shares fell 15% to $0.85. Zosano Pharma shares tumbled 43% on Thursday after the company announced it filed a voluntary petition for relief under chapter 11.
    • Gravitas Education Holdings, Inc. (NYSE:GEHI) declined 13.8% to $0.60.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 13.6% to $0.2878.
    • Minerva Neurosciences, Inc. (NASDAQ:NERV) dipped 12.4% to $0.3703.
    • Context Therapeutics Inc. (NASDAQ:CNTX) declined 10.5% to $1.96.
    • Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) dropped 10.4% to $2.10.
    • Wayfair Inc. (NYSE:W) dipped 8.7% to $58.22.
    • Talkspace, Inc. (NASDAQ:TALK) fell 8.5% to $1.61 after jumping 34% on Thursday.
    • Impac Mortgage Holdings, Inc. (NYSE:IMH) dropped 8% to $0.7598.
    • Zhong Yang Financial Group Limited (NASDAQ:TOP) fell 6.1% to $15.21 amid post-IPO volatility.
    • Zumiez Inc. (NASDAQ:ZUMZ) fell 5.2% to $32.38 after the company reported worse-than-expected Q1 EPS results and issued Q2 EPS and sales guidance below analyst estimates.

     

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AMLX
    $BQ
    $BTOG

    CompanyDatePrice TargetRatingAnalyst
    Okta Inc.
    $OKTA
    1/14/2026$120.00Equal-Weight → Overweight
    Stephens
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    Wayfair Inc.
    $W
    1/7/2026$123.00Equal Weight → Overweight
    Barclays
    Okta Inc.
    $OKTA
    12/16/2025$125.00Hold → Buy
    Jefferies
    Talkspace Inc.
    $TALK
    12/9/2025$3.50Equal Weight
    Barclays
    Wayfair Inc.
    $W
    12/3/2025$94.00Buy → Hold
    Jefferies
    Okta Inc.
    $OKTA
    12/3/2025$112.00 → $90.00Market Perform
    BMO Capital Markets
    Okta Inc.
    $OKTA
    12/3/2025$125.00 → $110.00Buy
    Needham
    More analyst ratings

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Okta upgraded by Stephens with a new price target

    Stephens upgraded Okta from Equal-Weight to Overweight and set a new price target of $120.00

    1/14/26 8:22:37 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Nurix Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00

    1/8/26 8:12:12 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wayfair upgraded by Barclays with a new price target

    Barclays upgraded Wayfair from Equal Weight to Overweight and set a new price target of $123.00

    1/7/26 8:45:23 AM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACOR
    $AMLX
    $BQ
    $BTOG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Huang Chiao Chieh bought $600,001 worth of shares (262,009 units at $2.29), increasing direct ownership by 23% to 1,421,219 units (SEC Form 4)

    4 - ENERGY FOCUS, INC/DE (0000924168) (Issuer)

    12/31/25 9:21:21 AM ET
    $EFOI
    Building Products
    Consumer Discretionary

    Director Firestone Karen bought $100,845 worth of shares (8,100 units at $12.45), increasing direct ownership by 15% to 63,100 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    12/23/25 8:48:33 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nicholas & Melinda Gerber Living Trust bought $23,175 worth of shares (25,000 units at $0.93), increasing direct ownership by 0.13% to 18,751,125 units (SEC Form 4)

    4 - Marygold Companies, Inc. (0001005101) (Issuer)

    12/12/25 12:12:16 PM ET
    $MGLD
    Finance: Consumer Services
    Finance

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

    SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi® (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable or metastatic) melanoma. Amtagvi is the first one-time T cell therapy for a solid tumor cancer as well as the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and ta

    2/5/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Marygold Companies Reports Financial Results For its Second Fiscal Quarter Ended December 31, 2025

    The Marygold Companies, Inc. (the "Company") (NYSE:MGLD), a global holding firm with a focus on financial services, today reported financial results for its second fiscal quarter ended December 31, 2025. Revenue for the three months ended December 31, 2025, amounted to $7.6 million, compared with the prior year period, when revenues were $8.0 million and which also included $0.6 million from Brigadier Security Systems (2000) Ltd. ("Brigadier"), a wholly owned subsidiary that was sold in July 2025 for $2.5 million. The Company's net loss for the quarter was $0.6 million as compared with a net loss of $1.7 million for the second quarter of the prior fiscal year. The $1.1 million improvement

    2/5/26 5:00:00 PM ET
    $MGLD
    Finance: Consumer Services
    Finance

    Affirm and Wayfair expand partnership to the UK and Canada

    Affirm (NASDAQ:AFRM) today announced the expansion of its partnership with Wayfair (NYSE:W), bringing its honest financial products to shoppers in the UK and Canada. Whether shopping for a new dining table or the perfect sofa, approved shoppers in the UK and Canada can now split their purchases with Affirm. The experience is straightforward: customers receive a quick, real-time approval decision and can choose the payment plan that fits their needs. Affirm never charges late fees or hidden fees, and there is no compounding interest. Customers only pay what they agree to. Today's announcement builds on the companies' recently expanded partnership, which brought Affirm to Wayfair's onli

    2/5/26 4:15:00 PM ET
    $AFRM
    $W
    Finance: Consumer Services
    Finance
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer, Secretary Reilly John Charles was granted 20,542 shares, increasing direct ownership by 2% to 1,038,685 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    2/4/26 8:34:35 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Director Frost Diana covered exercise/tax liability with 548 units of Class A Common Stock, decreasing direct ownership by 10% to 5,128 units (SEC Form 4)

    4 - Wayfair Inc. (0001616707) (Issuer)

    2/4/26 4:38:51 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    Co-Chief Executive Officer Cohen Joshua B sold $227,593 worth of shares (15,500 units at $14.68), decreasing direct ownership by 0.46% to 3,363,965 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    2/4/26 4:05:16 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AMLX
    $BQ
    $BTOG
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Society Pass Incorporated

    S-1/A - SOCIETY PASS INCORPORATED. (0001817511) (Filer)

    2/6/26 5:26:07 PM ET
    $SOPA
    Real Estate

    Society Pass Incorporated filed SEC Form 8-K: Other Events

    8-K - SOCIETY PASS INCORPORATED. (0001817511) (Filer)

    2/6/26 5:00:27 PM ET
    $SOPA
    Real Estate

    Wayfair Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Wayfair Inc. (0001616707) (Filer)

    2/6/26 4:15:11 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by HashiCorp Inc.

    SC 13G/A - HashiCorp, Inc. (0001720671) (Subject)

    11/14/24 5:45:37 PM ET
    $HCP
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by HashiCorp Inc.

    SC 13G/A - HashiCorp, Inc. (0001720671) (Subject)

    11/14/24 5:42:58 PM ET
    $HCP
    EDP Services
    Technology

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Financials

    Live finance-specific insights

    View All

    The Marygold Companies Reports Financial Results For its Second Fiscal Quarter Ended December 31, 2025

    The Marygold Companies, Inc. (the "Company") (NYSE:MGLD), a global holding firm with a focus on financial services, today reported financial results for its second fiscal quarter ended December 31, 2025. Revenue for the three months ended December 31, 2025, amounted to $7.6 million, compared with the prior year period, when revenues were $8.0 million and which also included $0.6 million from Brigadier Security Systems (2000) Ltd. ("Brigadier"), a wholly owned subsidiary that was sold in July 2025 for $2.5 million. The Company's net loss for the quarter was $0.6 million as compared with a net loss of $1.7 million for the second quarter of the prior fiscal year. The $1.1 million improvement

    2/5/26 5:00:00 PM ET
    $MGLD
    Finance: Consumer Services
    Finance

    Talkspace to Report Fourth Quarter and Full Year 2025 Results and Host Conference Call

    NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Talkspace (NASDAQ:TALK),  a leading behavioral healthcare company, today announced that it will release its fourth quarter and full year 2025 results on Thursday, February 19, 2026 before market open and host a conference call to review the results at 8:30am ET. Conference Call DetailsThe conference call will be available via audio webcast at https://investors.talkspace.com/ and can also be accessed by dialing (800) 225-9448 for U.S. participants, or (203) 518-9708 for international participants, and using conference ID TALKQ425. A replay will be available shortly after the call's completion and remain available for approximately 90 days. About

    2/5/26 4:05:00 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    StoneCo Ltd. to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on March 02nd, 2026

    George Town, Grand Cayman--(Newsfile Corp. - January 22, 2026) - StoneCo Ltd. (NASDAQ:STNE) ("Stone") today announces that it will release its fourth quarter and fiscal year 2025 financial results on Monday, March 02nd, 2026, after the market closes. The Company will also host a conference call to discuss its results on the same day at 5:00pm ET (7:00pm BRT).The conference call can be accessed live over the Zoom webinar (ID: 869 7892 3413| Password: 164760). You can also access the meeting over the phone by dialing +1 646 931 3860 or +1 669 444 9171 from the U.S. Callers from Brazil can dial +55 21 3958 7888. Callers from the UK can dial +44 330 088 5830. The call will also be webcast live a

    1/22/26 7:32:00 AM ET
    $STNE
    EDP Services
    Technology

    $ACOR
    $AMLX
    $BQ
    $BTOG
    Leadership Updates

    Live Leadership Updates

    View All

    StoneCo Announces New CEO, Reinforcing Continuity and Execution

    George Town, Grand Cayman--(Newsfile Corp. - January 7, 2026) - StoneCo Ltd. (NASDAQ:STNE) ("Stone" or "the Company") announces today that Mr. Pedro Zinner has informed the Board of Directors of his decision to resign from his position as Chief Executive Officer, effective March 2026, for personal reasons.Mr. Zinner assumed the role of CEO three years ago, following his service on the Company's Board, at a critical moment in Stone's trajectory. During his tenure, Stone executed a clear strategic pivot, including the divestment of non-core assets such as Linx, the implementation of broad streamlining initiatives, the establishment of a disciplined capital allocation framework, and meaningful

    1/7/26 7:10:00 AM ET
    $STNE
    EDP Services
    Technology

    Okta Names Rob Bernshteyn and Paul Sagan to Board of Directors

    Okta, Inc. (NASDAQ:OKTA), the leading independent identity partner, today announced the appointment of Rob Bernshteyn and Paul Sagan to the Company's board of directors, effective December 19, 2025. "Rob and Paul bring a wealth of operational experience across SaaS, cybersecurity, and AI that will help drive Okta's next phase of growth," said Todd McKinnon, Okta CEO and Co-Founder. "Their expertise comes at a pivotal moment, as identity becomes the foundation for secure AI. With their leadership, we'll continue strengthening Okta's position as the neutral identity partner and accelerating our work to help customers safely adopt AI agents." "Okta has proven that identity is critical to sec

    12/19/25 4:01:00 PM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care